BioSpace News Archive

Data highlight a need for bladder-sparing therapies to improve outcomes for patients with high-grade, non-muscle invasive bladder cancer

Collegium Pharmaceutical, Inc. announced the pricing of its offering of $125,000,000 aggregate principal amount of 2.625% convertible senior notes due 2026 in a public offering registered under the Securities Act of 1933, as amended.

Further to my previous statements, as Chief Public Health Officer, I have assessed additional individuals in quarantine at Canadian Forces Base Trenton pursuant to an Emergency Order under the Quarantine Act and determined that they do not pose a risk of significant harm to public health.

Aethlon Medical, Inc., a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, reported financial results for its third quarter ended December 31, 2019 and provided an update on recent developments.

Universal Health Services, Inc. announced that it will report results for its fourth quarter and full year ended December 31, 2019 after the market closes on Wednesday, February 26, 2020.

Revance Therapeutics, Inc. announced that it intends to offer, subject to market conditions and other factors, $200 million aggregate principal amount of convertible senior notes due 2027 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Retrophin, Inc. announced it will report fourth quarter and full year 2019 financial results on Monday, February 24, 2020 after the close of the U.S. financial markets.

STERIS plc announced financial results for its fiscal 2020 third quarter ended December 31, 2019.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that the option agreement between KalVista and Merck related to intravitreal diabetic macular edema (DME) candidate KVD001 and future oral DME molecules has expired.

Renowned Stanford University specialist joins Hoag to bring care for Marfan Syndrome and Related Conditions to the Jeffrey M. Carlton Heart & Vascular Institute